טוען...
Ranibizumab in diabetic macular edema
By 2050 the prevalence of diabetes will more than triple globally, dramatically increasing the societal and financial burden of this disease worldwide. As a consequence of this growth, it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema (DME)...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Co., Limited
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3874491/ https://ncbi.nlm.nih.gov/pubmed/24379922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4239/wjd.v4.i6.310 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|